The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pégorier, S.
Right arrow Articles by Pretolani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pégorier, S.
Right arrow Articles by Pretolani, M.
The Journal of Immunology, 2006, 177: 4861-4869.
Copyright © 2006 by The American Association of Immunologists, Inc.

Eosinophil-Derived Cationic Proteins Activate the Synthesis of Remodeling Factors by Airway Epithelial Cells1

Sophie Pégorier*, Lori A. Wagner{dagger}, Gerald J. Gleich{dagger},{ddagger} and Marina Pretolani2,*

* Institut National de la Santé et de la Recherche Médicale, Unité 700, Université Paris 7, Faculté de Médecine Denis Diderot, Site Xavier Bichat, Paris, France; and {dagger} Department of Dermatology and {ddagger} Department of Medicine, University of Utah, Salt Lake City, UT 84132


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Eosinophil cationic proteins influence several biological functions of the respiratory epithelium, yet their direct contribution to airway remodeling has not been established. We show that incubation of the human bronchial epithelial cell line, BEAS-2B, or primary cultured human bronchial epithelial cells, normal human bronchial epithelial cells, with subcytotoxic concentrations (0.1, 0.3, and 1 µM) of major basic protein (MBP), or eosinophil peroxidase (EPO), augmented the transcripts of endothelin-1, TGF-{alpha}, TGF-beta1, platelet-derived growth factor (PDGF)-beta, epidermal growth factor receptor, metalloproteinase (MMP)-9, fibronectin, and tenascin. A down-regulation of MMP-1 gene expression was observed exclusively in BEAS-2B cells. Cationic protein-induced transcriptional effects were followed by the release of endothelin-1, PDGF-AB in the supernatants by ELISA, and by a down- and up-regulation, respectively, in the levels of MMP-1 and MMP-9 in cell lysates, by Western blot. Cell stimulation with the synthetic polycation, poly-L-arginine, reproduced some but not all effects of MBP and EPO. Finally, simultaneous cell incubation with the polyanion molecules, poly-L-glutamic acid or heparin, restored MMP-1 gene expression but incompletely inhibited MBP- and EPO-induced transcriptional effects as well as endothelin-1 and PDGF-AB release, suggesting that cationic proteins act partially through their cationic charge. We conclude that eosinophil-derived cationic proteins are able to stimulate bronchial epithelium to synthesize factors that influence the number and behavior of structural cells and modify extracellular matrix composition and turnover.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Eosinophil accumulation and activation in target tissues are associated with numerous diseases including infection with helminthic parasites, bronchial asthma, atopic allergy, and a number of malignant disorders (1, 2, 3, 4). Increased numbers of eosinophils are found in blood, bronchial tissue, bronchoalveolar lavage fluid, and induced sputum from asthmatic patients (3, 4, 5) and the extent of their activation correlates with disease severity (4). By releasing cytokines, lipid mediators, reactive oxygen species, and highly charged cytotoxic granular proteins, activated eosinophils contribute to airway inflammation and cause damage of the bronchial mucosa (3, 4). Increasing evidence indicates that eosinophils are also important effector cells involved in airway remodeling (6), a phenomenon characterized by subepithelial fibrosis, with fibroblast and myofibroblast accumulation beneath the subepithelial basement membrane, increased TGF-beta1 expression, and excessive extracellular matrix (ECM)3 protein and metalloproteinase (MMP) deposition in the stroma underlying the bronchial epithelium (7, 8). Thus, in vivo maneuvers aimed at removing eosinophils from blood and tissues prevented TGF-beta1 release and ECM protein accumulation in the airways (9, 10, 11, 12, 13, 14). Other features of airway remodeling seen in asthma include an increase in smooth muscle mass, goblet cell hyperplasia, and new blood vessel formation (7, 8). The end result is increased thickness of the bronchial wall, leading to a reduction in the airway caliber, an exaggerated airway narrowing, and a progressive decline of respiratory function (7, 8, 15).

The primary target of eosinophils is the bronchial epithelium whose functions and integrity are profoundly altered by eosinophil-secreted products, particularly cationic proteins, including major basic protein (MBP), eosinophil peroxidase (EPO), eosinophil cationic protein, and eosinophil-derived neurotoxin (16, 17). Most of the effects of these proteins on airway epithelium are mediated by cytotoxic mechanisms, or involve their cationic charge and high arginine content (17, 18, 19, 20, 21). Thus, synthetic cationic polypeptides, such as poly-L-arginine, mimic many of the effects of MBP, including bronchial hyperreactivity, mast cell and basophil activation, and increase in epithelial permeability (20, 21, 22, 23). It is noteworthy, however, that the cationic nature of eosinophil granule proteins may not fully explain their biological functions and, accordingly, the direct transcriptional or posttranscriptional effects of subcytotoxic concentrations of MBP have been described in various cell types, including basophils and lung fibroblasts (24, 25)

The respiratory epithelium is believed to orchestrate airway remodeling through aberrant production of ECM components, fibrogenic cytokines and chemokines, growth factors and MMPs, responsible for the proliferation, migration, and activation of airway smooth muscle cells and fibroblasts and for the differentiation of fibroblasts into myofibroblasts (26, 27). Although several stimuli generated in the asthmatic airways may potentially activate the respiratory epithelium, the possibility that eosinophil granule cationic proteins may directly promote the synthesis of remodeling factors has not received attention.

In this study, we provide evidence for the first time that the eosinophil granule proteins, MBP and EPO, directly up-regulate remodeling factor gene expression and protein release in cultured human airway epithelial cells and that these effects involve partly their cationic nature. Collectively, these findings establish a tangible link between eosinophil degranulation and airway remodeling, and identify a novel therapeutic target for eosinophil-mediated diseases.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Eosinophil-derived cationic protein purification

Eosinophils from patients with marked blood eosinophilia (up to 84%) were collected by cytapheresis and eosinophil granules and granule proteins were purified, as previously described (28, 29, 30). Briefly, after cell lysis and granule isolation, granules were solubilized in 0.01 M/L HCl (pH 2.0) by vigorous suspension with a Pasteur pipette. After centrifugation (13,600 x g, 5 min), the supernatant was fractionated on a Sephadex G-50 column equilibrated with 0.025 M/L sodium acetate, 0.15 M/L NaCl (pH 4.3). Individual protein peaks were pooled, and protein concentrations were determined by absorbance at 280 nm with the following extinction coefficients at 280 nM: E1% 1 cm, 14.5 for EPO (29) and 36.7 for MBP (30). All eosinophil granule protein preparations were pure as assessed by Coomassie blue staining after SDS-PAGE.

Epithelial cell culture and stimulation

The human bronchial epithelial cell line, BEAS-2B (American Type Culture Collection-LGC Promochem) (31) and primary cultured normal human bronchial epithelial cells (NHBE; Cambrex BioScience) were seeded in 6-well plastic plates (TPP-AG) previously coated with 2.5 mg/ml collagen type I (Sigma-Aldrich) in 0.016 mM acetic acid. Cells were grown at 37°C in a humidified 5% CO2 atmosphere in bronchial epithelium growth medium (Cambrex) supplemented with 0.5 ng/ml recombinant human epidermal growth factor (EGF), 500 ng/ml hydrocortisone, 0.005 mg/ml insulin, 0.035 mg/ml bovine pituitary extract, 500 nM ethanolamin, 500 nM phosphoethanolamin, 0.01 mg/ml transferrin, 6.5 ng/ml 3,3',5-triiodothyronine, 500 ng/ml adrenaline, and 0.1 ng/ml retinoic acid.

Once they reached ~80% confluence, epithelial cells were stimulated for 1, 3, 6, 24, and 48 h with 0.1, 0.3, and 1 µM MBP, or EPO, or with their vehicle, i.e., 0.025 M sodium acetate buffer with 0.15 M NaCl (pH 4.3). The addition of the acetate buffer failed to alter appreciably the pH of the culture medium. In the experiments aimed at determining whether the cationic charge of cationic proteins plays a role in the production of remodeling factors, cells were stimulated at selected time points with 1 µM MBP or EPO in the presence of 1 µM poly-L-glutamic acid (molecular mass 3,000–15,000; Sigma-Aldrich), or of 100 U/ml heparin (Grade IA, porcine intestinal mucosa; Sigma-Aldrich), or they were incubated with 1 µM of the synthetic polycation, poly-L-arginine (molecular mass 5,000–15,000; Sigma-Aldrich) instead of cationic proteins.

Assessment of epithelial cell viability

The effect of cationic proteins on epithelial cell viability was determined by quantifying lactate dehydrogenase (LDH) activity using a commercially available kit (Cytotoxicity Detection kit, LDH; Roche) according to the manufacturer’s instructions. Epithelial cells were seeded in 24-well plates (TPP) and stimulated with 1 µM MBP, EPO, or poly-L-arginine for 1, 3, 6, 24, and 48 h. Cells were harvested by a 15-min incubation in cell dissociation buffer (Invitrogen Life Technologies) at 37°C and pelleted by centrifugation (150 x g, 5 min, 4°C). Supernatants were further centrifuged before use. Three independent experiments were conducted. Results were calculated as a percentage of LDH activity from supernatants, in relation to cell pellets. The plates were then read on a Microplate reader photometer (Multiskan Ascent; Thermo) at 570-nm wavelength.

RNA isolation and reverse transcription

Confluent epithelial cells that had been cultured for 1–48 h in medium supplemented with 0.1, 0.3, and 1 µM MBP, or with 1 µM EPO, or poly-L-arginine, in the absence or the presence of 1 µM poly-L-glutamic acid or 100 U/ml heparin, were recovered in RA1 buffer contained in the NucleoSpin RNA II kit (Macherey-Nagel) supplemented with 3.5 µl of 2-ME (Sigma-Aldrich) and then stored at –80°C. Total RNAs were isolated using this same kit according to manufacturer’s instructions and quantified by measuring the OD at 260 nm. Reverse transcription was performed for 2 h at 37°C using Moloney murine leukemia virus reverse transcriptase (Invitrogen Life Technologies) and 2.5 µg/50 µl total RNA were used.

Real-time quantitative PCR

Real-time quantitative PCR was performed using the SYBRGreen JumpStart Taq Ready Mix detection kit (Sigma-Aldrich). In all assays, cDNA was amplified using a standardized program (2 min JumpStart Taq Polymerase activation step at 94°C; 40 cycles of 30 s at 94°C and 1 min at 60°C). All assays were performed in a volume of 20 µl, and primers were used at a final concentration of 0.33 µM. Reactions were conducted using the PCR ABI 7700 apparatus (Applied Biosystems). Transcripts showing cycle threshold (Ct) values >35 were considered to have minimal expression and were excluded from further analyses. For a more accurate and reliable normalization of the results, the intensity of gene expression was calculated using Ct <35 and it was normalized to the geometrical mean of the levels of transcripts encoding the most stable 3 housekeeping genes hypoxanthine-guanine-phosphoribosyl transferase 1 (HPRT1), succinate dehydrogenase (SDHA), and ribosomal protein 13a (RPL13a; Ref. 32). Normalization and calculation were assessed using GenNorm Software (Microsoft Excel, 2001 version). Primers were designed using Primer Express 2 Software (Applied Biosystems) and were synthesized by Invitrogen Life Technologies. Primer sequences and basal gene expression in vehicle-stimulated BEAS-2B and NHBE cells are described in Table I.


View this table:
[in this window]
[in a new window]
  		Table I. Real-time primer sequences and basal levels of transcript expression in human bronchial epithelial cellsa

 
Determination of platelet-derived growth factor (PDGF)-AB and endothelin-1 (ET-1) in cell supernatant

The levels of PDGF-AB and ET-1 were assessed in supernatants from epithelial cells stimulated for 6, 24, and 48 h with 1 µM MBP, EPO, or poly-L-arginine, in the absence or presence of 1 µM poly-L-glutamic acid or 100 U/ml heparin by ELISAs (human PDGF-AB Quantikine Immunoassay and human ET-1 QuantiGlo Immunoassay all obtained from R&D Systems Europe), respectively. The threshold of sensitivities was 31.2 pg/ml for PDGF-AB and 0.32 pg/ml for ET-1.

Assessment of MMP-1 and MMP-9 in cell lysates

Unstimulated and MBP-, EPO-, and poly-L-arginine (1 µM)-stimulated epithelial cells, in the absence or presence of 1 µM poly-L-glutamic acid or 100 U/ml heparin were harvested by a 15-min incubation in cell dissociation buffer at 37°C, then lysed and sonicated with a buffer containing NaCl (150 mM), HEPES (10 mM, pH 8), saccharose (500 mM), Na2 EDTA (1 mM), Nonidet P40 (40%, Igepal; Sigma-Aldrich). Protein contents in clarified supernatants were determined by comparison with an OVA standard curve (ICN Biomedical), using the Bio-Rad protein assay.

The expression of MMP-1 and of MMP-9 were assessed by Western blot after protein fractionation (50 µg) by 10% SDS-PAGE, transfer to polyvinylidene difluoride membranes (Bio-Rad) and sequential reaction with a chicken anti-human MMP-1 Ab (clone 3.4.24.7, 1/2000 dilution; Interchim), or with a goat anti-human MMP-9 Ab (clone AB911, 1/1000 dilution; R&D Systems) and with a mouse anti-beta-actin mAb (clone AC-74, 1/4000 dilution; Sigma-Aldrich). Immunoblots were then incubated with peroxidase-conjugated goat anti-chicken, donkey anti-goat, or donkey anti-mouse Abs at a 1/3000 dilution and developed using the ECL Western blotting detection system (all from Amersham). The intensities of the expression of MMP-1, MMP-9, and beta-actin were quantified using a densitometer (CCD-COHU) and Gel Analyst software (Claravision). Results are expressed as a ratio, defined as the OD values of the MMP-1 or MMP-9 bands/OD values of the corresponding beta-actin bands.

Statistical analysis

Data were analyzed statistically using the StatView SE+Graphics program for Macintosh (Abacus Concepts). Comparability between the means was assessed by Wilcoxon test for the MBP dose-response experiments, and ANOVA test for the experiments with MBP, EPO, and poly-L-arginine in the absence or the presence of heparin or poly-L-glutamic acid. The results are expressed as means ± SEM for the indicated number of experiments.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Effect of cationic proteins on epithelial cell viability

Changes in the viability of BEAS-2B and NHBE cells upon 1–48 h of stimulation with the highest concentration of cationic proteins and poly-L-arginine i.e., 1 µM, were determined by assessing LDH release. MBP, EPO, and poly-L-arginine failed to induce the release of amounts of LDH above those detected in vehicle-treated cells (between 15 and 20% release, differences not statistically significant, data not shown).

Effect of cationic proteins and poly-L-arginine on the expression of transcripts encoding remodeling factors

The ability of MBP and EPO and of the surrogate cationic molecule, poly-L-arginine, to influence the expression of factors involved in airway remodeling was investigated by real-time quantitative PCR (Figs. 1-4 and Table II). We found detectable levels of the transcripts encoding ET-1, TGF-{alpha}, TGF-beta1, EGFR, PDGF-beta, MMP-1, MMP-9, fibronectin, and tenascin in vehicle (acetate buffer)-stimulated human BEAS-2B cells and in NHBE cells isolated from three distinct healthy donors (Ct < 35, Table I). The highest expressed transcripts in both cell types were those encoding EGFR and the two ECM proteins, fibronectin and tenascin (Table I). However, the basal expression level of MMP-1 mRNA was higher in NHBE, as compared with BEAS-2B cells (mean Ct values of 20.9 and 30.0, respectively, Table I).


Figure 1
View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 1. MBP and poly-L-arginine modulate the levels of mRNA encoding remodeling factors in the human bronchial epithelial cell line, BEAS-2B. BEAS-2B cells were stimulated for 3, 6, and 24 h with 0.1, 0.3, and 1 µM MBP, with 1 µM poly-L-arginine, or with the vehicle of MBP, i.e., sodium acetate buffer. Cells were harvested, RNA was extracted, reverse transcribed, and a real-time quantitative PCR for ET-1 (A), TGF-{alpha} (B), EGFR (C), TGF-beta1 (D), and PDGF-beta (E) was performed. Results are expressed as the ratio of each transcript relative to the geometrical average of mRNA expression of the housekeeping genes HPRT1, SDHA, and RPL13a. Data are means ± SEM of five independent experiments. *, p < 0.05, as compared with vehicle-treated cells.

 

Figure 2
View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 2. MBP and poly-L-arginine induce changes in the levels of mRNA encoding MMPs and extracellular matrix proteins in BEAS-2B cells. BEAS-2B cells were stimulated for 3, 6, and 24 h with 0.1, 0.3, and 1 µM MBP, with 1 µM poly-L-arginine, or with the vehicle of MBP, i.e., sodium acetate buffer, and the expression of mRNA for MMP-1 (A), MMP-9 (B), tenascin (C), and fibronectin (D) was assessed by real-time quantitative PCR and results are expressed as described in the legend of Fig. 1. Data are means ± SEM of five independent experiments. *, p < 0.05, as compared with vehicle-treated cells.

 

Figure 3
View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 3. Poly-L-glutamic acid modulates MBP- and EPO-induced changes in the levels of transcripts encoding remodeling factors in BEAS-2B cells. BEAS-2B cells were stimulated with 1 µM MBP, EPO, or their vehicle, i.e., sodium acetate buffer, or with 1 µM poly-L-glutamic acid (poly-L-glu) alone, or in association with cationic proteins. Cells were collected at 3 h, for ET-1 (A) and TGF-beta1 (D), or at 24 h, for TGF-{alpha} (B), EGFR (C), and PDGF-beta (E) and real-time quantitative PCR for these factors was performed, as described in the legend of Fig. 1. Data are means ± SEM of three independent experiments. *, p < 0.05, as compared with vehicle-treated cells; {dagger}, p < 0.05, as compared with poly-L-glutamic acid-treated cells; and {ddagger}, p < 0.05, as compared with MBP- or EPO-stimulated cells.

 

Figure 4
View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 4. Poly-L-glutamic acid modulates MBP- and EPO-induced changes in the levels of transcripts encoding MMPs and ECM proteins in BEAS-2B cells. BEAS-2B cells were stimulated as described in the legend of Fig. 3 and real-time quantitative PCR was assessed at 3 h, for tenascin (C), and at 24 h, for MMP-1 (A), MMP-9 (B), and fibronectin (D). Data are means ± SEM of three independent experiments. *, p < 0.05, as compared with vehicle-treated cells; {dagger}, p < 0.05, as compared with poly-L-glutamic acid-treated cells, and {ddagger}, p < 0.05, as compared with MBP- or EPO-stimulated cells.

 

View this table:
[in this window]
[in a new window]
  		Table II. Effect of poly-L-arginine, MBP, and EPO on the levels of the transcripts encoding remodeling factors in primary cultured human bronchial epithelial cells (NHBE) and modulation by poly-L-glutamic acid

 
Incubation of BEAS-2B cells over 3–24 h in the presence of 0.1, 0.3, and 1 µM MBP significantly up-regulated the expression of mRNA for ET-1, TGF-{alpha}, EGFR, TGF-beta1, PDGF-beta, MMP-9, tenascin, and fibronectin (Figs. 1 and 2, B–D). Under these conditions, MMP-1 transcripts were significantly reduced (Fig. 2A). No changes in the levels of any of the transcripts examined were noted after 1 h of stimulation (data not shown). Similar induction of ET-1, TGF-{alpha}, TGF-beta1, EGFR, PDGF-beta, and tenascin gene expression and down-regulation of MMP-1 transcription was observed in EPO (1 µM)-stimulated cells (Fig. 3 and Fig. 4, A and C), but contrary to MBP, this cationic protein failed to alter MMP-9 and fibronectin mRNA levels (Fig. 4, B and D).

Cell stimulation with 1 µM poly-L-arginine up-regulated the levels of the transcripts encoding ET-1, TGF-{alpha}, EGFR, and PDGF-beta to a similar extent as MBP (Fig. 1, A–C and E). However, poly-L-arginine failed to augment TGF-beta1, MMP-9, tenascin, and fibronectin gene expression (Figs. 1D and 2, B–D) and, contrary to MBP and EPO, it augmented the levels of the transcripts encoding MMP-1 (Fig. 2A).

Most of the above findings were confirmed in NHBE cells, where 1 µM MBP and EPO augmented ET-1, TGF-{alpha}, TGF-beta1, EGFR, PDGF-beta, MMP-9, and fibronectin mRNA, without altering the levels of MMP-1 transcripts (Table II). In addition, MBP, but not EPO, increased significantly tenascin gene expression, as compared with vehicle-treated cells. Under these conditions, cell stimulation with 1 µM poly-L-arginine up-regulated exclusively ET-1, TGF-beta1, EGFR, and MMP-9 mRNAs (Table II).

Poly-L-glutamic acid and heparin partially reverse cationic protein-induced effects

To further establish whether the cationic charge of MBP and EPO was involved in their modulatory activities, we examined the effect of 1 µM poly-L-glutamic acid and of 100 U/ml heparin on MBP- and EPO- (1 µM) induced changes in the expression of the different transcripts. For these experiments, we selected the time points corresponding to the highest MBP- and EPO-mediated stimulation or inhibition of gene expression, i.e., 3 h for ET-1, TGF-beta1, and tenascin and 24 h for TGF-{alpha}, EGFR, PDGF-beta, MMP-1, MMP-9, and fibronectin (Figs. 1 and 2) in BEAS-2B cells, and 3 h for ET-1, 6 h for TGF-beta1 and 24 h for TGF-{alpha}, EGFR, PDGF-beta, MMP-1, MMP-9, fibronectin, and tenascin in NHBE cells (Table II). Simultaneous incubation of poly-L-glutamic acid with MBP or EPO reduced significantly the levels of the transcripts encoding ET-1, TGF-{alpha}, TGF-beta1, EGFR, PDGF-beta, fibronectin, tenascin, and MMP-9 in BEAS-2B and NHBE cells (Fig. 3 and Table II). In addition, poly-L-glutamic acid partially reversed MBP- and EPO-induced decrease in MMP-1 mRNA in BEAS-2B cells (Fig. 4). Poly-L-glutamic acid by itself, significantly down-regulated MMP-1 gene expression in BEAS-2B cells (Fig. 4A), without altering the basal levels of the other transcripts analyzed. Similar results were obtained using 100 U/ml heparin instead of poly-L-glutamic acid (data not shown).

Eosinophil-derived cationic proteins and poly-L-arginine generate remodeling factors

To determine whether the transcriptional effects of cationic proteins and of poly-L-arginine resulted in proportionate changes in the elaboration of the corresponding proteins, we measured the levels of selected factors in the supernatants of MBP-, EPO-, and poly-L-arginine (1 µM) stimulated BEAS-2B and NHBE cells by ELISA (Figs. 5, A and B, and 6, A and B), or in whole cell protein extracts, by Western blot (Figs. 5, C and D, and 6C). By ELISA, we established that MBP and poly-L-arginine generated amounts of ET-1 and PDGF-AB above those measured in vehicle-treated BEAS-2B and NHBE cells, whereas EPO augmented exclusively PDGF-AB levels (Figs. 5, A and B, and 6, A and B). In parallel, Western blot analysis revealed lower expression of MMP-1 in MBP- and EPO- as compared with vehicle-stimulated cells (Figs. 5C and 6C). Poly-L-arginine significantly augmented MMP-1 levels in BEAS-2B cells (Fig. 5C), whereas it down-regulated the levels of MMP-1 in NHBE cells (Fig. 6C). A comparable increase in the expression of MMP-9 in response to poly-L-arginine-, MBP- and EPO- was observed in BEAS-2B and NHBE cells (Figs. 5D and 6C).


Figure 5
View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 5. Poly-L-glutamic acid modulates MBP-, EPO-, and poly-L-arginine-induced production of remodeling factors by BEAS-2B cells. BEAS-2B cells were stimulated for 6, 24, and/or 48 h with 1 µM MBP, EPO, poly-L-arginine (poly-L-arg), or with the vehicle of cationic proteins, i.e., sodium acetate buffer, or with 1 µM poly-L-glutamic acid (poly-L-glu), alone, or in association with cationic proteins. The concentrations of PDGF-AB (A) and ET-1 (B) were measured in the cell-free supernatants by specific ELISAs. The levels of cell-associated MMP-1 (C) and MMP-9 (D) were assessed by immunoblot in protein extracts from BEAS-2B cells stimulated for 24 h. The intensity of the expression of MMP-1 (54 kDa) and MMP-9 (67 kDa) were quantified by densitometry. Values are expressed as a ratio, defined as the OD values MMP-1 or MMP-9 bands/OD value of the corresponding beta-actin bands. A representative Western blot profile of MMP-1 and of MMP-9 expression is shown under the corresponding graph. Results are the means ± SEM of three distinct experiments. *, p < 0.05, as compared with vehicle-treated cells; {dagger}, p < 0.05, as compared with poly-L-glutamic acid-treated cells, and {ddagger}, p < 0.05, as compared with MBP-, EPO-, or poly-L-arginine-stimulated cells.

 

Figure 6
View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 6. Poly-L-glutamic acid modulates MBP-, EPO-, and poly-L-arginine-induced production of remodeling factors by primary cultured NHBE. Cells were stimulated for 6, 24, and/or 48 h with 1 µM MBP, EPO, poly-L-arginine (poly-L-arg), or with the vehicle of cationic proteins, i.e., sodium acetate buffer, or with 1 µM poly-L-glutamic acid (poly-L-glu), alone, or in association with cationic proteins. The concentrations of PDGF-AB (A) and ET-1 (B) were measured in the cell-free supernatants by specific ELISAs. The levels of cell-associated MMP-1 and MMP-9 (C) were assessed by immunoblot in protein extracts from NHBE cells stimulated for 24 h. The intensity of the expression of MMP-1 (25 kDa) and MMP-9 (67 kDa) were quantified by densitometry as explained in the legend of Fig. 5. Results are the means ± SEM of three independent experiments performed with cells from three distinct donors. *, p < 0.05, as compared with vehicle-treated cells; {dagger}, p < 0.05, as compared with poly-L-glutamic acid-treated cells, and {ddagger}, p < 0.05, as compared with MBP-, EPO-, or poly-L-arginine-stimulated cells.

 
To establish whether the cationic charge of MBP and EPO accounted for these modulatory effects, experiments were conducted in the absence or presence of 1 µM poly-L-glutamic acid. Poly-L-glutamic acid, by itself, slightly but significantly increased spontaneous PDGF-AB generation at 48 h in both BEAS-2B and NHBE cells (Figs. 5A and 6A), but it failed to modify MBP-, EPO-, and poly-L-arginine-induced PDGF-AB and ET-1 release at any time point in BEAS-2B cells (Fig. 5, A and B). This contrasts with NHBE cells, where poly-L-glutamic acid inhibited significantly poly-L-arginine-, MBP- and EPO-induced PDGF-AB and ET-1 release.

Poly-L-glutamic acid also prevented MBP- and EPO-induced decrease in the levels of MMP-1, without altering MMP-9 expression in both types of epithelial cells (Fig. 5, C and D, and Fig. 6C). Finally, poly-L-glutamic acid suppressed poly-L-arginine-induced MMP-1 expression in NHBE cells (Fig. 6C). Similar modulation of the effects of MBP and EPO on protein generation was observed upon the addition of heparin to the culture medium instead of poly-L-glutamic acid (data not shown).


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The possibility that eosinophil-derived cationic proteins directly stimulate the respiratory epithelium to generate factors involved in the onset and progression of airway remodeling has not been investigated. To test this hypothesis, we characterized the effects of two different native purified human cationic proteins, i.e., MBP and EPO, on the synthesis and production of mesenchymal and airway smooth muscle growth factors, MMPs and ECM proteins, in the human cell line, BEAS-2B, which was originally established from healthy bronchial epithelium (33), and confirmed the most relevant results in primary human NHBE cells. We conducted these experiments using concentrations of cationic proteins (0.1, 0.3, and 1 µM) that had been used in other studies of their effector functions and that failed to induce epithelial cell cytotoxicity (34, 35, 36, 37). Importantly, these concentrations of cationic proteins were even lower that those measured in peripheral blood of atopic individuals and in the airways of asthmatics (38, 39).

We found that both MBP and EPO increased the levels of the transcripts encoding ET-1, TGF-{alpha}, TGF-beta1, EGFR, PDGF-beta, and tenascin in both BEAS-2B and NHBE cells. Under these conditions, cationic proteins down-regulated MMP-1 gene expression in BEAS-2B cells, without altering its levels in NHBE cells. In addition, MBP, but not EPO, up-regulated MMP-9 and fibronectin mRNAs in BEAS-2B cells, whereas both MBP and EPO increased these genes in NHBE cells.

To establish whether cationic protein-induced remodeling factor gene expression was associated with proportionate changes in the synthesis of the corresponding proteins, we measured the concentrations of ET-1 and PDGF-AB in the cell supernatants by specific ELISAs and the expression of cell-associated MMP-1 and MMP-9 by Western blot. Cell stimulation with MBP promoted both ET-1 and PDGF-AB release, whereas EPO increased the levels of PDGF-AB, but not of ET-1. In addition, Western blot analyses demonstrated lower amounts of MMP-1 and higher levels of MMP-9 in whole protein extracts from MBP- and EPO- as compared with vehicle-stimulated cells. Collectively, these results indicate that the transcriptional effects of MBP and EPO result in proportionate changes in the synthesis of some, but not all proteins and that these two cationic proteins do not necessarily share all activity-related effects, suggesting that they may use different pathways to activate gene transcription and protein synthesis in airway epithelial cells.

The expression of most of the remodeling factors that we have analyzed was increased in asthmatic airways, including in association with the bronchial epithelium, and it was frequently correlated with disease severity (6, 7, 40, 41, 42, 43, 44, 45, 46, 47). These factors modulate several aspects of airway remodeling, as suggested by in vitro studies. Thus, EGFR is likely to play an important role in bronchial epithelial repair in asthma, and its excessive expression and abnormal function contribute to subepithelial fibrosis (26, 40). TGF-{alpha}, one of the ligands of EGFR that regulates lung remodeling and morphogenesis (47), is induced in patients with chronic inflammatory lung diseases characterized by tissue remodeling, including asthma (46). TGF-beta1 elicits differentiation of fibroblasts into myofibroblasts, which, in turn, secrete interstitial collagen and other fibrogenic growth factors (48). PDGF-beta regulates airway smooth muscle cell proliferation, chemotaxis, and activation (49, 50, 51), and contributes to lung fibroblast growth (52). ET-1 is a 21-aa peptide that plays an important role in the pathogenesis of airway remodeling by inducing collagen secretion by lung fibroblasts and fibronectin synthesis by bronchial epithelial cells, and by amplifying EGF-induced airway smooth muscle cell proliferation (53, 54, 55). Finally, MMPs govern ECM turnover and degradation, and regulate inflammation and repair processes (56). Increased or misregulated levels of MMP-9 are believed to contribute to chronic airway inflammation and remodeling in asthma (45).

Among the remodeling factors examined, MMP-1 was unique in showing a marked down-regulation in response to cationic proteins. MMP-1 degrades fibrillary collagen (56) and temporal and spatial expression studies revealed its early increase in migrating corneal epithelial and stromal cells at the wound edge (57). In addition, recent data demonstrated that defective wound closure resulting from the exposure of human bronchial epithelial cells to diesel exhaust particles was accompanied by a selective decrease in MMP-1 expression (58), indicating that MMP-1 plays an important role in the early phases of epithelial cell migration and repair (59). Together, these findings and our present observations suggest that, by inhibiting MMP-1 synthesis, eosinophil granule proteins may contribute to collagen accumulation on the one hand, and delay epithelial regeneration after damage, on the other.

Many of the in vitro and in vivo biological properties of MBP and EPO are mediated by their cationic charge, as determined by the inhibitory activity of anionic molecules, such as heparin and polyanions (18, 19, 20, 25, 60). Here we demonstrated that mixing MBP or EPO with poly-L-glutamic acid or with heparin down-regulated ET-1, TGF-{alpha}, EGFR, TGF-beta1, PDGF-beta, MMP-9, tenascin, and fibronectin gene expression and restored the levels of MMP-1 mRNA, suggesting that the charge of these cationic proteins plays an important role in their stimulatory potential. However, poly-L-glutamic acid, by itself, reduced the levels of MMP-1 mRNA (but not the expression of the corresponding protein) and promoted PDGF-AB release. These observations underline the difficulty to firmly conclude that the effects of poly-L-glutamic acid or of heparin on the synthesis and release of remodeling factors in response to MBP and EPO that we presently describe, are exclusively the result of the contrasting charge of these molecules. Nevertheless, we showed that the surrogate cationic molecule, poly-L-arginine, reproduced most of the effects of MBP and EPO in both BEAS-2B and NHBE cells. These include the increase in the levels of ET-1, TGF-beta1, EGFR, and MMP-9 mRNAs, the release of ET-1 and PDGF-AB in cell supernatants and the production of cell-associated MMP-9. Overall, these observations support a dominant role for the cationic charge in mediating some, but not all transcriptional and posttranscriptional effects of MBP and EPO on airway epithelial cells. Several hypotheses may explain the disparity in the effects observed between poly-L-arginine, MBP and EPO. These include, for example, their marked differences in tertiary conformation and in the proportion of arginine and other amino acid residues, which may influence their charge and interactions with cell environment (61, 62). In addition and contrary to MBP, EPO belongs to the peroxidase superfamily, which possesses catalytic properties that confer a wide panel of potential activations (62, 63). Finally, Fuchs et al. (64) demonstrated that arginine residues of poly-L-arginine facilitate its transduction in endocytic vesicles of living cells, whereas MBP has a poor solubility and a tendency to polymerize with itself and with other proteins. In contrast, although remaining as a monomeric molecule, EPO may interact with other molecules of its environment, leading to altered biological activities (64).

To our knowledge, few reports have investigated links between eosinophil-derived cationic proteins and airway remodeling in vitro. An early study demonstrated that eosinophil-cationic protein inhibited proteoglycan degradation in human lung fibroblasts suggesting that eosinophil degranulation may participate in the generation of pulmonary fibrosis (65). More recently, Rochester et al. (25) showed that MBP synergized with IL-1{alpha} and TGF-beta1 to increase IL-6-type cytokine mRNA and protein synthesis by human lung fibroblasts, largely by acting through its cationic charge. However, under these conditions, type I collagen production and cell proliferation were unaffected, indicating that while MBP regulates certain biological functions in these cells, it does not increase collagen output. Finally, Zagai et al. (66) reported the ability of eosinophil-cationic protein to augment fibroblast-mediated collagen gel contraction, supporting the hypothesis that eosinophil-derived cationic proteins contribute to ECM remodeling by interacting directly with mesenchymal cells.

Persistent airway eosinophilia has been reported in severe asthmatics despite long-lasting, high-dose steroid therapy (67, 68). In these patients, irreversible structural changes of the bronchial wall characterized by subepithelial fibrosis, mucous gland, and airway smooth muscle hypertrophy and/or hyperplasia have been observed (7, 8, 69). Interestingly, a recent report demonstrated that a single allergen challenge in patients with mild asthma induced acute airway remodeling, with activation of epithelial cells and fibroblasts and increased ECM protein deposition within the reticular basement membrane (70). The temporal association between these structural alterations and eosinophil accumulation in the bronchial wall led to the hypothesis that eosinophil-derived products may contribute to a rapid onset of airway remodeling (70).

In conclusion, this study demonstrates that subcytotoxic concentrations of eosinophil cationic proteins influence the synthesis of bioactive molecules by epithelial cells that may disturb in vivo the function and behavior of structural cells and alter the composition of ECM. Hence, these observations argue for a causal relationship between eosinophil degranulation and airway remodeling in asthma and suggest that interventions targeting eosinophil cationic proteins may have a promising therapeutic application. Lastly, these findings have implications for other syndromes associated with fibrosis, such as retroperitoneal fibrosis and sclerosing cholangitis, where eosinophil infiltration and degranulation are prominent (71).


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by the "Agence Nationale de la Recherche" (Grant Number 0012405), by the Chancellerie des Universités de Paris en Sorbonne (fellowship to S.P.), Paris, France, and by the U.S. National Institutes of Health (Grant AI09728). Back

2 Address correspondence and reprint requests to Dr. Marina Pretolani, Institut National de la Santé et de la Recherche Médicale, Unité 700, Université Paris 7, Faculté de Médecine Denis Diderot, Site Xavier Bichat, 16 rue Henri Huchard, 75018 Paris, France. E-mail address: mpretol{at}bichat.inserm.fr Back

3 Abbreviations used in this paper: ECM, extracellular matrix; MMP, metalloproteinase; MBP, major basic protein; EPO, eosinophil peroxidase; NHBE, normal human bronchial epithelial cell; LDH, lactate dehydrogenase; Ct, cycle threshold; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; ET-1, endothelin-1. Back

Received for publication January 27, 2006. Accepted for publication July 17, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Kroegel, C., J. A. Warner, J.-C. Virchow, H. Matthys. 1994. Pulmonary immune cells in health and disease: the eosinophil leucocyte (part II). Eur. Respir. J. 7: 743-760. [Abstract]
  2. Butterfield, J. H., K. M. Leiferman. 1993. Eosinophil-associated diseases. H. Smith, and R. M. Cook, eds. The Handbook of Immunopharmacology, Immunopharmacology of Eosinophils 152-192. Academic Press, London.
  3. Jeffery, P. K., A. J. Wardlaw, F. C. Nelson, J. V. Collins, A. B. Kay. 1989. Bronchial biopsies in asthma. Am. Rev. Respir. Dis. 140: 1745-1753. [Medline]
  4. Bousquet, J., P. Chanez, J. Y. Lacoste, G. Barnéon, N. Ghavanian, I. Enander, P. Venge, S. Ahlstedt, J. Simony-Lafontaine, P. Godard, et al 1990. Eosinophilic inflammation in asthma. N. Engl. J. Med. 323: 1033-1039. [Abstract]
  5. Djukanovic, R., W. R. Roche, J. W. Wilson, C. R. W. Beasley, O. P. Twentyman, P. H. Howarth. 1990. Mucosal inflammation in asthma. Am. Rev. Respir. Dis. 142: 434-457. [Medline]
  6. Kay, A. B., S. Phipps, D. S. Robinson. 2004. A role for eosinophils in airway remodeling in asthma. Trends Immunol. 25: 477-482. [Medline]
  7. Bousquet, J., P. Jeffery, W. W. Busse, M. Johnson, A. M. Vignola. 2000. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 161: 1720-1745. [Free Full Text]
  8. Jeffery, P. K.. 2001. Remodeling in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164: S28-S38. [Abstract/Free Full Text]
  9. Trifilieff, A., Y. Fujitani, A. J. Coyle, M. Kopf, C. Bertrand. 2001. IL-5 deficiency abolishes aspects of airway remodelling in a murine model of lung inflammation. Clin. Exp. Allergy 31: 934-942. [Medline]
  10. Cho, J. Y., M. Miller, K. J. Baek, J. W. Han, J. Nayar, S. Y. Lee, K. McElwain, S. McElwain, S. Friedman, D. H. Broide. 2004. Inhibition of airway remodeling in IL-5-deficient mice. J. Clin. Invest. 113: 551-560. [Medline]
  11. Tanaka, H., M. Komai, K. Nagao, M. Ishizaki, D. Kajiwara, K. Takatsu, G. Delespesse, H. Nagai. 2004. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am. J. Respir. Cell Mol. Biol. 31: 62-68. [Abstract/Free Full Text]
  12. Humbles, A. A., C. M. Lloyd, S. J. McMillan, D. S. Friend, G. Xanthou, E. E. McKenna, S. Ghiran, N. P. Gerard, C. Yu, S. H. Orkin, et al 2004. A critical role for eosinophils in allergic airway remodeling. Science 305: 1776-1779. [Abstract/Free Full Text]
  13. Lee, J. J., D. Dimina, M. P. Macias, S. I. Ochkur, M. P. McGarry, K. R. O’Neill, C. Protheroe, R. Pero, T. Nguyen, S. A. Cormier, et al 2004. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305: 1773-1776. [Abstract/Free Full Text]
  14. Flood-Page, P., A. Menzies-Gow, S. Phipps, S. Ying, A. Wangoo, M. S. Ludwig, N. Barnes, D. Robinson, A. B. Kay. 2003. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial basement membrane of mild atopic asthmatics. J. Clin. Invest. 112: 1029-1036. [Medline]
  15. Lange, P., J. Parner, J. Vestbo, P. Schnohr, G. Jensen. 1998. A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 339: 1194-1200. [Abstract/Free Full Text]
  16. Gleich, G. J., E. Frigas, D. A. Loegering, D. L. Wassom, D. Steinmuller. 1979. Cytotoxic properties of the eosinophil major basic protein. J. Immunol. 123: 2925-2927. [Abstract/Free Full Text]
  17. Hamann, K. J., R. L. Barker, R. M. Ten, G. J. Gleich. 1991. The molecular biology of eosinophil granule proteins. Int. Arch. Allergy Appl. Immunol. 94: 202-209. [Medline]
  18. Barker, R. L., R. H. Gundel, G. J. Gleich, J. L. Checkel, D. A. Loegering, L. R. Pease, K. J. Hamann. 1991. Acidic polyamino acids inhibit human eosinophil granule major basic protein toxicity: evidence of a functional role for ProMBP. J. Clin. Invest. 88: 798-805. [Medline]
  19. Gundel, R. H., L. G. Letts, G. J. Gleich. 1991. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J. Clin. Invest. 87: 1470-1473. [Medline]
  20. Coyle, A. J., S. J. Ackerman, C. G. Irvin. 1993. Cationic proteins induce airway hyperresponsiveness dependent on charge interactions. Am. Rev. Respir. Dis. 147: 896-900. [Medline]
  21. O’Donnell, M. C., S. J. Ackerman, G. J. Gleich, L. L. Thomas. 1983. Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J. Exp. Med. 157: 1981-1991. [Abstract/Free Full Text]
  22. Uchida, D. A., S. J. Ackerman, A. J. Coyle, G. L. Larsen, P. F. Weller, J. Freed, C. G. Irvin. 1993. The effect of human eosinophil granule major basic protein on airway responsiveness in the rat in vivo: a comparison with polycations. Am. Rev. Respir. Dis. 147: 982-988. [Medline]
  23. Herbert, C. A., D. Edwards, J. R. Boot, C. Robinson. 1991. In vitro modulation of the eosinophil-dependent enhancement of the permeability of the bronchial mucosa. Br. J. Pharmacol. 104: 391-398.
  24. Thomas, L. L., H. Kubo, D. J. Loegering, K. Spillard, A. J. Weaver, D. J. McCormick, C. Weiler, G. J. Gleich. 2001. Peptide-based analysis of amino acid sequences important to the biological activity of eosinophil granule major basic protein. Immunol. Lett. 78: 175-181. [Medline]
  25. Rochester, C. L., S. J. Ackerman, T. Zheng, J. A. Elias. 1996. Eosinophil-fibroblast interactions: granule major basic protein interacts with IL-1 and transforming growth factor-beta in the stimulation of lung fibroblast IL-6-type cytokine production. J. Immunol. 156: 4449-4456. [Abstract]
  26. Holgate, S. T., D. E. Davies, P. M. Lackie, S. J. Wilson, S. M. Puddicombe, J. L. Lordan. 2000. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J. Allergy Clin. Immunol. 105: 193-204. [Medline]
  27. Knight, D. A., C. L. Lane, S. M. Stick. 2004. Does aberrant activation of the epithelial-mesenchymal trophic unit play a key role in asthma or is it an unimportant sideshow?. Curr. Opin. Pharmacol. 4: 251-256. [Medline]
  28. Gleich, G. J., D. A. Loegering, K. G. Mann, J. E. Maldonado. 1976. Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. J. Clin. Invest. 57: 633-640. [Medline]
  29. Carlson, M. G., C. G. Peterson, P. Venge. 1985. Human eosinophil peroxidase: purification and characterization. J. Immunol. 134: 1875-1879. [Abstract]
  30. Plager, D. A., D. A. Loegering, D. A. Weiler, J. L. Checkel, J. M. Wagner, N. J. Clarke, S. Naylor, S. M. Page, L. L. Thomas, I. Akerblom, et al 1999. A novel and highly divergent homolog of human eosinophil granule major basic protein. J. Biol. Chem. 274: 14464-14473. [Abstract/Free Full Text]
  31. Lechner, J. F., M. A. LaVeck. 1985. A serum-free method for culturing normal human bronchial epithelial cells at clonal density. J. Tissue Culture Methods 9: 43-48. [Medline]
  32. Vandesompele, J., K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paepe, F. Speleman. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Gen. Biol. 3: 1-11.
  33. Ke, Y., R. R. Reddel, B. I. Gerwin, M. Miyashita, M. McMenamin, J. F. Lechner, C. C. Harris. 1988. Human bronchial epithelial cells with integrated SV40 virus T antigen genes retain the ability to undergo squamous differentiation. Differentiation 38: 60-66. [Medline]
  34. Motojima, S., E. Frigas, D. A. Loegering, G. J. Gleich. 1989. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am. Rev. Respir. Dis. 139: 801-805. [Medline]
  35. Kubo, H., D. A. Loegering, Y. Tohda, J. Bankers-Fulbright, C. R. Weiler, H. Nakajima, L. L. Thomas, C. R. Adolphson, G. J. Gleich. 1999. Discordant and anomalous results among cytotoxicity assays: the confounding properties of eosinophil granule major basic protein on cell viability assays. J. Immunol. Methods 227: 1-15. [Medline]
  36. Tagari, P., P. Chee, C. Chan, K. McKee, C. Black, D. Nicholson, A. W. Ford-Hutchinson. 1992. Quantitation of eosinophil major basic protein cytotoxicity to rodent respiratory epithelium. Agents Actions 37: 171-173. [Medline]
  37. Barker, R. L., R. H. Gundel, G. J. Gleich, J. L. Checkel, D. A. Loegering, L. R. Pease, K. J. Hamann. 1991. Acidic polyamino acids inhibit human eosinophil granule major basic protein toxicity: evidence of a functional role for ProMBP. J. Clin. Invest. 88: 798-805. [Medline]
  38. Wassom, D. L., D. A. Loegering, G. O. Solley, S. B. Moore, R. T. Schooley, A. S. Fauci, G. J. Gleich. 1981. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J. Clin. Invest. 67: 651-661. [Medline]
  39. Frigas, E., D. A. Loegering, G. O. Solley, G. M. Farrow, G. J. Gleich. 1981. Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. Mayo Clin. Proc. 56: 345-353. [Medline]
  40. Puddicombe, S. M., R. Polosa, A. Richter, M. T. Krishna, P. H. Howarth, S. T. Holgate, D. E. Davies. 2000. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J. 14: 1362-1374. [Abstract/Free Full Text]
  41. Redington, A. E., D. R. Springall, Q. H. Meng, A. B. Tuck, S. T. Holgate, J. M. Polak, P. H. Howarth. 1997. Immunoreactive endothelin in bronchial biopsy specimens: increased expression in asthma and modulation by corticosteroid therapy. J. Allergy Clin. Immunol. 100: 544-552. [Medline]
  42. Minshall, E. M., D. Y. M. Leung, R. J. Martin, Y. L. Song, L. Cameron, P. Ernst, Q. Hamid. 1997. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 17: 326-333. [Abstract/Free Full Text]
  43. Vignola, A. M., P. Chanez, G. Chiappara, A. Merendino, E. Pace, A. Rizzo, A. M. la Rocca, V. Bellia, G. Bonsignore, J. Bousquet. 1997. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. 156: 591-599. [Abstract/Free Full Text]
  44. Hoshino, M., Y. Nakamura, J. J. Sim. 1998. Expression of growth factors and remodelling of the airway wall in bronchial asthma. Thorax 53: 21-27. [Abstract]
  45. Wenzel, S. E., S. Balzar, M. Cundall, H. W. Chu. 2003. Subepithelial basement membrane immunoreactivity for metalloproteinase 9: association with asthma severity, neutrophilic inflammation and wound repair. J. Allergy Clin. Immunol. 111: 1345-1352. [Medline]
  46. Amishima, M., M. Munakata, Y. Nasuhara, A. Sato, T. Takahashi, Y. Homma, Y. Kawakami. 1998. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am. J. Respir. Crit. Care Med. 157: 1907-1912. [Medline]
  47. Bonner, J. C.. 2002. The epidermal growth factor receptor at the crossroads of airway remodeling. Am. J. Physiol. 283: L528-L530.
  48. Annes, J. P., J. S. Munger, D. B. Rifkin. 2003. Making sense of latent TGF beta activation. J. Cell Sci. 116: 217-224. [Abstract/Free Full Text]
  49. Hirst, S. J., P. J. Barnes, C. H. Twort. 1996. PDGF isoform-induced proliferation and receptor expression in human cultured airway smooth muscle cells. Am. J. Physiol. 270: L415-L428. [Medline]
  50. Walker, T. R., S. M. Moore, M. F. Lawson, R. A. Panettieri, Jr, E. R. Chilvers. 1998. Platelet-derived growth factor-BB and thrombin activate phosphoinositide 3-kinase and protein kinase B: role in mediating airway smooth muscle proliferation. Mol. Pharmacol. 54: 1007-1015. [Abstract/Free Full Text]
  51. Hedges, J. C., M. A. Dechert, I. A. Yamboliev, J. L. Martin, E. Hickey, L. A. Weber, W. T. Gerthoffer. 1999. A role for p38MAPK/HSP27 pathway in smooth muscle cell migration. J. Biol. Chem. 274: 24211-24219. [Abstract/Free Full Text]
  52. Ingram, J. L., A. B. Rice, K. Geisenhoffer, D. K. Madtes, J. C. Bonner. 2004. IL-13 and IL-1beta promote lung fibroblast growth through coordinated up-regulation of PDGF-AA and PDGF-R{alpha}. FASEB J. 18: 1132-1134. [Abstract/Free Full Text]
  53. Peacock, A. J., K. E. Dawes, A. Shock, A. J. Gray, J. T. Reeves, G. J. Laurent. 1992. Endothelin-1 and endothelin-3 induces chemotaxis and replication of pulmonary artery fibroblasts. Am. J. Respir. Cell Mol. Biol. 7: 492-499. [Medline]
  54. Marini, M., S. Carpi, A. Bellini, F. Patalano, S. Mattoli. 1996. Endothelin-1 induces fibronectin expression in human bronchial epithelial cells. Biochem. Biophys. Res. Commun. 220: 896-899. [Medline]
  55. Panettieri, R. A., R. G. Goldie, P. J. Rigby, A. J. Eszterhas, D. W. Hay. 1996. Endothelin-1-induced potentiation of human airway smooth muscle proliferation: an ETA receptor-mediated phenomenon. Br. J. Pharmacol. 118: 191-197. [Medline]
  56. Parks, W. C., C. L. Wilson, Y. S. López-Boado. 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4: 617-629. [Medline]
  57. Daniels, J. T., G. Geerling, R. A. Alexander, G. Murphy, P. T. Khaw, U. Saarialho-Kere. 2003. Temporal and spatial expression of matrix metalloproteinases during wound healing of human corneal tissue. Exp. Eye Res. 77: 653-664. [Medline]
  58. Doornaert, B., V. Leblond, S. Galiacy, G. Gras, E. Planus, V. Laurent, D. Isabey, C. Lafuma. 2003. Negative impact of DEP exposure on human airway epithelial cell adhesion, stiffness, and repair. Am. J. Physiol. 284: L119-L132.
  59. Daniels, J. T., G. A. Limb, U. Saarialho-Kere, G. Murphy, P. T. Khaw. 2003. Human corneal epithelial cells require MMP-1 for HGF. Invest. Ophthalmol. Vis. Sci. 44: 1048-1055. [Abstract/Free Full Text]
  60. Fryer, A. D., D. B. Jacoby. 1992. Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate. J. Clin. Invest. 90: 2292-2298. [Medline]
  61. Temkin, V., H. Aingorn, L. Puxeddu, O. Goldshmidt, E. Zcharia, G. J. Gleich, I. Vlodavsky, F. Levi-Schaffer. 2004. Eosinophil major basic protein: first identified natural heparanase-inhibiting protein. J. Allergy Clin. Immunol. 113: 703-709. [Medline]
  62. Thomsen, A. R., L. Sottrup-Jensen, G. J. Gleich, C. Oxvig. 2000. The status of half-cystine residues and locations of N-glycosylated asparagine residues in human eosinophil peroxidase. Arch. Biochem. Biophys. 379: 147-152. [Medline]
  63. Furtmuller, P. G., M. Zederbauer, W. Jantschko, J. Helm, M. Bogner, C. Jakopitsch, C. Obinger. 2006. Active site structure and catalytic mechanisms of human peroxidases. Arch. Biochem. Biophys. 445: 199-213. [Medline]
  64. Fuchs, S. M., R. T. Raines. 2004. Pathway for polyarginine entry into mammalian cells. Biochemistry 43: 2438-2444. [Medline]
  65. Hernnas, J., B. Sarnstrand, P. Lindroth, C. G. Peterson, P. Venge, A. Malmstrom. 1992. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur. J. Cell Biol. 59: 352-363. [Medline]
  66. Zagai, U., C. M. Skold, A. Trulson, P. Venge, J. Lundahl. 2004. The effect of eosinophils on collagen gel contraction and implication for tissue remodeling. Clin. Exp. Immunol. 135: 427-433. [Medline]
  67. Wenzel, S. E., L. B. Schwatz, E. L. Langmarck, J. L. Halliday, J. B. Trudeau, R. L. Gibbs, H. W. Chu. 1999. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 160: 1001-1008. [Abstract/Free Full Text]
  68. ten Brinke, A., A. H. Zwinderman, P. J. Sterk, K. F. Rabe, E. H. Bel. 2004. Refractory eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am. J. Respir. Crit. Care Med. 170: 601-605. [Abstract/Free Full Text]
  69. Benayoun, L., A. Druilhe, M. C. Dombret, M. Aubier, M. Pretolani. 2003. Airway structural alterations selectively associated with severe asthma. Am. J. Respir. Crit. Care Med. 167: 1360-1368. [Abstract/Free Full Text]
  70. Phipps, S., F. Benyahia, T. T. Ou, J. Barkans, D. S. Robinson, A. B. Kay. 2004. Acute allergen-induced airway remodeling in atopic asthma. Am. J. Respir. Cell Mol. Biol. 31: 626-632. [Abstract/Free Full Text]
  71. Noguchi, H., G. M. Kephart, T. V. Colby, G. J. Gleich. 1992. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am. J. Pathol. 140: 521-528. [Abstract]



This article has been cited by other articles:


Home page
 GutHome page
D J Mulder, I Pacheco, D J Hurlbut, N Mak, G T Furuta, R J MacLeod, and C J Justinich
FGF9-induced proliferative response to eosinophilic inflammation in oesophagitis
Gut, February 1, 2009; 58(2): 166 - 173.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
E. Morschl, J. G. Molina, J. B. Volmer, A. Mohsenin, R. S. Pero, J.-S. Hong, F. Kheradmand, J. J. Lee, and M. R. Blackburn
A3 Adenosine Receptor Signaling Influences Pulmonary Inflammation and Fibrosis
Am. J. Respir. Cell Mol. Biol., December 1, 2008; 39(6): 697 - 705.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
A.H. Nissim Ben Efraim and F. Levi-Schaffer
Review: Tissue remodeling and angiogenesis in asthma: the role of the eosinophil
Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 163 - 171.
[Abstract] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A. Druilhe, J.-M. Zahm, L. Benayoun, D. El Mehdi, M. Grandsaigne, M.-C. Dombret, I. Mosnier, B. Feger, J. Depondt, M. Aubier, et al.
Epithelium Expression and Function of Retinoid Receptors in Asthma
Am. J. Respir. Cell Mol. Biol., March 1, 2008; 38(3): 276 - 282.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Q. Gu, M. E. Wiggers, G. J. Gleich, and L.-Y. Lee
Sensitization of isolated rat vagal pulmonary sensory neurons by eosinophil-derived cationic proteins
Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L544 - L552.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
J. Eriksson, C. Woschnagg, E. Fernvik, and P. Venge
A SELDI-TOF MS study of the genetic and post-translational molecular heterogeneity of eosinophil cationic protein
J. Leukoc. Biol., December 1, 2007; 82(6): 1491 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
R. Shaykhiev and R. Bals
Interactions between epithelial cells and leukocytes in immunity and tissue homeostasis
J. Leukoc. Biol., July 1, 2007; 82(1): 1 - 15.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pégorier, S.
Right arrow Articles by Pretolani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pégorier, S.
Right arrow Articles by Pretolani, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS